Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohn's Disease

Abstract

Performances of assays for IFX and anti-IFX Abs are comparable. However, IFX concentrations and anti-IFX Ab titers show systematic differences, and in individual patients, only the same assay should be used. Problems may arise when different assays are used to manage therapies in the same patient.